LAUSR

Background Psoriasis (PSO) and Psoriatic Arthritis, (PsA) particularly moderate to severe disease (MS-PSO), are inflammatory systemic conditions that are associated with a high risk of cardiovascular (CV) complications further beyond the increased prevalence of classical risk factors in this population. Consequently, the early identification of patients with MS-PSO and PsA who may benefit from primary CV prevention is essential. However, medical providers do not routinely screen or counsel their patients for CV risk factors or comorbidities. In addition, paucity of robust clinical data complicates the implementation of management protocols for primary CV prevention in MS-PSO and PsA. Objectives To generate expert-based recommendations on the management of CV comorbidities in patients with MS-PSO and PsA through the application of the Delphi technique. Methods The development of Delphi-based recommendations included four steps: (1) systematic literature review to explore current information and clinical recommendations on management of CV comorbidities in patients with PsO and PsA; (2) two subsequent meetings with project coordinators (n = 3) and scientific advisors (n = 7) from different medical specialties (rheumatology, dermatology, endocrinology, internal medicine, pneumology, rehabilitation, psychiatry and primary care) to examine the results of the review and decide which statements should be included in the final version of the questionnaire; (3) a two-round Delphi questionnaire aimed at specialists in rheumatology and dermatology to assess the degree of consensus on the different points raised; (4) finally, a face-to-face meeting with the project coordinators and scientific advisors to discuss and ratify the results of the Delphi process. Results As a result of the literature review and the assessment and approval of scientific advisors, the final version of the Delphi survey contains 52 statements grouped into 35 questions. The questionnaire is divided into 3 topic sections: (1) identification, diagnosis and referral of MS-PSO and/or PsA patients with CV comorbidities (n = 12 statements); (2) management and treatment of CV comorbidities associated with MS-PSO and/or PsA (n = 36); (3) influence of MS-PSO and/or PsA treatments on CV comorbidities and vice versa (n = 4). Conclusion This Delphi-based study may fill an important gap in the evidence by providing relevant information on the management of CV comorbidities in patients with MS-PSO and/or PsA. Disclosure of Interests RAQUEL ALMODOVAR: None declared, Jose Luís López Estebaranz Consultant for: I have received fees as an advisory board member for Pfizer, Novartis, Leo Pharma, Lilly, Celgene, Abbvie and Janssen cilad, Speakers bureau: I have received fees as a speaker for Pfizer, Novartis, Leo Pharma, Lilly, Celgene, Abbvie and Janssen cilad, Eva De Higes Martínez : None declared, María Jesús López Navas : None declared, Carlos Guijarro Herraiz Consultant for: I have received payments as an advisor for Amgen, Esteve, Ferrer, MSD, Pfizer, Rubió and Sanofi., Speakers bureau: I have received payments as a speaker for Amgen, Esteve, Ferrer, MSD, Pfizer, Rubió and Sanofi., Juan José Gorgojo Martínez : None declared, David Palacios : None declared, José Carlos Peláez Álvarez Consultant for: I have received payments for consultancies from Shire Pharmaceuticals Ibérica, Pfizer, Merck Sharp Dohme España and Laboratorios Farmaceuticos Rovi., Speakers bureau: I have received lecture fees from Shire Pharmaceuticals Ibérica, Pfizer, Merck Sharp Dohme España and Laboratorios Farmaceuticos Rovi., Diana Ruiz Genao Consultant for: I have received payments for consultancies from Janssen-Cilag,Pfizer, Abbvie, Celgene, Leo Pharma, Novartis, Speakers bureau: I have received lecture fees from Janssen-Cilag,Pfizer, Abbvie, Celgene, Leo Pharma, Novartis., Lucía Pérez Carbonell : None declared, Susana Gómez Employee of: I am a current employee of Pfizer., Erica Falkelbach Employee of: I am a current employee of Pfizer., Francisco Rebollo Employee of: I am a current employee of Pfizer., Pedro Zarco Montejo : None declared